Pharmaceuticals company Senores Pharmaceuticals announced 9MFY25 & Q3FY25 results Q3FY25 Financial Highlights: Income: Rs 106.4 crore compared to Rs 78.7 crore during Q3FY24, change 35%. EBITDA: Rs 29.1 crore compared to Rs 15.2 crore during Q3FY24, change 92%. EBITDA margin: 27.3% for Q3FY25. PAT: Rs 17.2 crore compared to Rs 7.1 crore during Q3FY24, change 142%. PAT margin: 16.1% for Q3FY25. 9MFY25 Financial Highlights: Income: Rs 288.1 crore compared to Rs 112.1 crore during Q3FY24, change 157%. EBITDA: Rs 74.3crore compared to Rs 19.2 crore during Q3FY24, change 287%. EBITDA margin: 25.8% for Q3FY25. PAT: Rs 40.7 crore compared to Rs 15.5 crore during Q3FY24, change 162%. PAT margin: 14.1% for Q3FY25. Swapnil Shah, Managing Director, Senores Pharmaceuticals, said: “We are pleased to report strong performance for Q3 and 9MFY25, driven byour strategy of developing niche products for Regulated Markets andexpanding our CDMO/CMO operations. At the same time, we have continuedto grow our presence and product portfolio in Emerging Markets. Our revenue and profitability for 9MFY25 have increased by over 150% YoY, andwe are optimistic about sustaining this momentum going forward. In Regulated Markets, robust growth in the CDMO/CMO segment was partlyoffset by a softer performance in the Marketed Products segment, which wasimpacted by the high base of Q3FY24. The consolidation of acquiredbusinesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. YoY, the Regulated Markets and Emerging Marketsbusinesses grew by approximately 100% and over 10 times, respectively, for 9MFY25. In 9MFY25, we launched one new product and received ANDA approval forfive products in the Regulated Markets business, bringing our total ANDA approvals to 24. Our Emerging Markets business is growing well through portfolio andfootprint expansion. Our registered product portfolio in the Emerging Marketsbusiness expanded to 267 products. With a strong product portfolio, we are now realigning our go-to-market models to make our Emerging Marketsoperations more profitable. We are seeing significant traction and scale-up in our CDMO/CMO segment.Currently, we manufacture 21 products in this business and expect faster growth with the addition of new products, customers, and increased walletshare from existing customers. We remain focused on executing our business strategies across segments andare confident that healthy growth will continue in the year ahead.” Result PDF